Future Impact of mRNA Therapy on Cardiovascular Diseases

Abstract

The silver lining of the recent pandemic was that it accelerated the emergence of messenger ribonucleic acid (mRNA) therapeutics. The great promise of mRNA therapeutics was highlighted by the speed at which the vaccines were created, tested, and proven to be relatively safe and highly effective. There are a wide variety of mRNA therapeutics now under development, and dozens of these are in clinical trials. These therapeutics are generating a major paradigm shift in medical therapy, including the treatment of cardiovascular disease. Most of the cardiovascular mRNA therapies are still in preclinical development, although a phase 2a trial of mRNA therapy for myocardial ischemia has been completed with promising results. 1 The application of mRNA therapies to cardiovascular diseases is virtually limitless, and ongoing work includes mRNA therapies for myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and arterial occlusive diseases. In addition, mRNA may be used to enhance cell therapies. In the future, mRNA therapies for cardiovascular disease are destined to supplant some of our current biologics and pharmacotherapies and will be used to treat previously untreatable cardiovascular diseases. Furthermore, mRNA therapies can be personalized, and they can be rapidly generated in current Good Manufacturing Practice facilities with a modest footprint, facilitating the rise of hospital-based regional centers of RNA therapeutics.

Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention

“…In order to address these challenges and take advantage of the opportunities presented by emerging technologies, there is a need for collaboration among healthcare professionals, researchers, policymakers, and patients. By working together, we can improve the prevention, diagnosis, and treatment of CVDs and reduce the global burden of these diseases [120].…”

Subvalvular Aortic Stenosis: Learning From Human and Canine Clinical Research

“…In fact, research teams are currently working on mRNA therapeutics for the treatment of myocardial ischemia, heart failure, arrhythmias, arterial occlusive disease, and hypercholesterolemia. Recent advances, including improvements in mRNA delivery and encapsulation options, have made these therapies more viable [ 98 ]. RNA interference (RNAi) is a related but separate treatment option that involves silencing RNA binding to the 3’ untranslated region (UTR) of an mRNA transcript, resulting in decreased levels of translation or increased degradation of that transcript.…”

“…RNA interference (RNAi) is a related but separate treatment option that involves silencing RNA binding to the 3’ untranslated region (UTR) of an mRNA transcript, resulting in decreased levels of translation or increased degradation of that transcript. RNAi treatments for amyloidosis and hypercholesterolemia have been approved; others are in development [ 98 ]. The question that we are left with, then, is: Which RNA transcript(s) could be targeted to treat SAS?…”